Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 791 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Brain Tumor Recurrent Clear all
Completed Phase 2 Interventional

ANG1005 in Patients With Recurrent High-Grade Glioma

NCT01967810
View directory record Official record
Conditions
Glioma, Glioblastoma, Brain Tumor, Recurrent
Interventions
ANG1005, Bevacizumab
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
12
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated No phase listed Observational

Study of Stored Tumor Samples in Young Patients With Brain Tumors

NCT00897286
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 39 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

NCT02457845
View directory record Official record
Conditions
Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, PNET, Cerebral Primitive Neuroectodermal Tumor, Embryonal Tumor
Interventions
G207
Biological
Lead sponsor
Gregory K. Friedman, MD
Other
Eligibility
3 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

NCT00101270
View directory record Official record
Conditions
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Early Phase 1 Interventional

Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma

NCT00864864
View directory record Official record
Conditions
Glioblastoma, Brain Tumor
Interventions
Sunitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

NCT00107237
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
AEE788, everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Carmustine in Treating Patients With Recurrent Malignant Glioma

NCT00004028
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, conventional surgery
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Not applicable Interventional

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

NCT04132843
View directory record Official record
Conditions
Brain Neoplasm, Lymphoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Interventions
Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

NCT00883688
View directory record Official record
Conditions
Brain Cancer, Pediatric Cancers
Interventions
Bevacizumab, Lapatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

NCT01095094
View directory record Official record
Conditions
Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma
Interventions
ritonavir, lopinavir
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

NCT00005951
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

NCT00085566
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Prostate Cancer
Interventions
everolimus, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

NCT00617539
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors

NCT00006450
View directory record Official record
Conditions
Brain Tumor
Interventions
Phenylbutyrate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated Not applicable Interventional

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT02967380
View directory record Official record
Conditions
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Primary Melanocytic Lesion of Meninges, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma, Metastatic Malignant Neoplasm in the Brain, Multiple Sclerosis, Recurrent Adult Brain Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol, Gadopentetate Dimeglumine
Procedure · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma

NCT00070525
View directory record Official record
Conditions
Childhood High-grade Cerebral Astrocytoma, Childhood Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Results available

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

NCT02313272
View directory record Official record
Conditions
Malignant Glioma
Interventions
Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

NCT02774681
View directory record Official record
Conditions
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Cognitive Assessment, Palbociclib, Quality-of-Life Assessment, Trastuzumab
Procedure · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chicago, Illinois • Lake Forest, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 21, 2026, 10:14 AM EDT
Not listed Phase 1Phase 2 Interventional

Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

NCT00983398
View directory record Official record
Conditions
Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Germ Cell Tumor, Medulloblastoma, Medulloepithelioma, Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Germ Cell Tumor, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor
Interventions
Carboplatin, Mannitol, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sodium Thiosulfate
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

NCT00939991
View directory record Official record
Conditions
Brain Tumor, Glioblastoma
Interventions
Vorinostst/Bevacizumab/Temozolomide
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional

S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

NCT00003911
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 21, 2026, 10:14 AM EDT
Completed No phase listed Observational

Study of Blood and Cheek Cell Samples From Patients With Glioma

NCT01009307
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
polymorphism analysis, laboratory biomarker analysis, medical chart review
Genetic · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
1,709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

NCT00045734
View directory record Official record
Conditions
Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Meningeal Hemangiopericytoma, Adult Meningioma, Recurrent Adult Brain Tumor
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 21, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Young Patients With Gliomas

NCT00238264
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
radiation therapy
Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
127
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 109 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 21, 2026, 10:14 AM EDT